Physician profile
Paul P Ho
NPI 1730186677
$19,318.79
in general payments reported to CMS, 2019-2025
42 companies · $3,075 in 2025
The $3,075 reported for 2025 was more than what 88% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,307 · 2020: $1,575 · 2021: $1,987 · 2022: $3,409 · 2023: $2,799 · 2024: $3,167 · 2025: $3,075.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,245 · Travel and Lodging: $720 · Education: $75.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,245.08 |
| Travel and Lodging | $720.26 |
| Education | $75.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $6,936.60 | 2019-2025 | Selectra, Biomonitor, Amvia Edge |
| Boston Scientific Corporation | $1,930.46 | 2019-2025 | Lux-Dx Insertable Cardiac Monitor, Watchman Flx, General - Interventional Oncology |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $945.97 | 2021-2025 | Lifevest |
| Abbott Laboratories | $856.95 | 2019-2025 | Amplatzer Amulet, Cardiomems, Gallant |
| Janssen Pharmaceuticals, INC | $744.80 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $732.10 | 2019-2025 | Camzyos, Eliquis |
| Novo Nordisk INC | $634.87 | 2021-2025 | Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $612.50 | 2019-2025 | |
| Amgen INC. | $590.15 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $531.26 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $529.06 | 2021-2025 | Wainua, Brilinta, Farxiga |
| Impulse Dynamics (USA) INC. | $505.15 | 2022-2023 | Optimizer |
| Amarin Pharma, INC. | $450.99 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $440.94 | 2019-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $343.97 | 2019-2023 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $295.02 | 2022-2024 | Verquvo |
| Philips North America LLC | $268.43 | 2024-2025 | (5044) Mcot, Mcot |
| Atricure, INC. | $267.47 | 2019-2025 | Atriclip Laa Exclusion System, Epi-Sense Guided Coagulation System With Visitrax |
| Actelion Pharmaceuticals US, INC. | $226.69 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $218.92 | 2022-2025 | |
| Cvrx, INC. | $130.78 | 2025 | Barostim Neo System |
| Medtronic Vascular, INC. | $129.88 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $114.21 | 2019-2025 | Evkeeza |
| Alnylam Pharmaceuticals INC. | $102.16 | 2024-2025 | Amvuttra |
| Lexicon Pharmaceuticals, INC. | $97.97 | 2023-2024 | Inpefa |
| Heartflow, INC. | $93.37 | 2024-2025 | |
| Kiniksa Pharmaceuticals, LTD. | $73.56 | 2022-2023 | Arcalyst |
| Penumbra, INC. | $62.79 | 2025 | Indigo System |
| Edwards Lifesciences Corporation | $59.55 | 2023-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Bridgebio Pharma, INC. | $58.98 | 2025 | Attruby |
| Esperion Therapeutics, INC. | $46.46 | 2024-2025 | Nexletol |
| Abiomed | $45.09 | 2023-2024 | Impella |
| Medtronic, INC. | $37.39 | 2022 | |
| Lilly USA, LLC | $33.97 | 2019 | |
| Elutia, INC. | $27.99 | 2021 | |
| Cleerly, INC. | $25.10 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Kiniksa Pharmaceuticals International, Plc | $23.62 | 2024 | Arcalyst |
| Lundbeck LLC | $21.65 | 2019 | |
| Astellas Pharma US INC | $19.71 | 2019 | |
| Akcea Therapeutics, INC. | $18.31 | 2019 | |
| Inspire Medical Systems, INC. | $17.72 | 2023 | Inspire |
| Scpharmaceuticals INC. | $16.23 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Ho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.